{"altmetric_id":1124792,"counts":{"readers":{"mendeley":4,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["125822054141052"],"posts_count":1},"total":{"posts_count":1}},"citation":{"abstract":"Omalizumab (Xolair\u00ae) is a monoclonal antibody indicated for moderate to severe persistent allergic asthma patients with symptoms that are inadequately controlled with inhaled corticosteroids (ICS).","abstract_source":"pubmed","altmetric_jid":"4f6fa52a3cf058f610003f71","authors":["Marie-H\u00e9l\u00e8ne Lafeuille"],"doi":"10.3109\/02770903.2011.618568","first_seen_on":"2012-12-14T17:10:49+00:00","issns":["0277-0903"],"issue":"9","journal":"Journal of Asthma","last_mentioned_on":1318108708,"links":["http:\/\/informahealthcare.com\/doi\/abs\/10.3109\/02770903.2011.618568?ai=1lfw&amp%3Bmi=3gfofr&amp%3Baf=R"],"pmid":"21978232","pubdate":"2011-10-08T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["pulmonarymedicine","allergyandimmunology"],"title":"Concomitant Asthma Medication Use in Patients Receiving Omalizumab: Results from Three Large Insurance Claims Databases","type":"article","volume":"48","mendeley_url":"http:\/\/www.mendeley.com\/research\/concomitant-asthma-medication-patients-receiving-omalizumab-results-three-large-insurance-claims-dat-2"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":3630432,"mean":4.9299514944696,"rank":2899590,"this_scored_higher_than_pct":2,"this_scored_higher_than":79432,"rank_type":"exact","sample_size":3630432,"percentile":2},"similar_age_3m":{"total_number_of_other_articles":276829,"mean":5.6964141633072,"rank":220338,"this_scored_higher_than_pct":1,"this_scored_higher_than":957,"rank_type":"exact","sample_size":276829,"percentile":1},"this_journal":{"total_number_of_other_articles":674,"mean":3.4178751857355,"rank":605,"this_scored_higher_than_pct":2,"this_scored_higher_than":16,"rank_type":"exact","sample_size":674,"percentile":2},"similar_age_this_journal_3m":{"total_number_of_other_articles":51,"mean":4.01452,"rank":49,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":51,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":[],"by_discipline":[]}}},"posts":{"facebook":[{"title":"Concomitant Asthma Medication Use in Patients Receiving Omalizumab: Results from Three Large Insurance Claims Databases","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=229710153752241&id=125822054141052","citation_ids":[1124792],"posted_on":"2011-10-08T21:18:28+00:00","summary":"Journal of Asthma, Volume 0, Issue 0, Page 1-8, Early Online.","author":{"name":"Informa Healthcare: Respiratory Research","url":"https:\/\/www.facebook.com\/125822054141052","facebook_wall_name":"Informa Healthcare: Respiratory Research","image":"https:\/\/graph.facebook.com\/125822054141052\/picture","id_on_source":"125822054141052"}}]}}